| Serial Number | 97796226 |
| Word Mark | RESOLIAN |
| Filing Date | Wednesday, February 15, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, June 4, 2024 |
| Registration Number | 7410177 |
| Registration Date | Tuesday, June 4, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 9, 2024 |
| Goods and Services | Laboratory testing services in clinical research and clinical trials of innovator and generic medicines in the pharmaceutical and biotechnology fields; Research and development in the fields of bioanalysis, immunoassay development, bioanalytical assay validation and testing, biomarker studies, drug metabolism, and pharmacokinetic testing; Pharmaceutical research and development services; Chemical, bioanalytical, biological and biotechnology research services; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Pharmaceutical drug development services; Scientific testing in the fields of oncology, neurology, gastroenterology, immunology, endocrinology, gene therapy, infectious disease, rare and orphan diseases, cardiovascular disease, metabolic disease, central nervous system, ophthalmology, and respiratory diseases, for medical and pharmaceutical research purposes; Drug and chemical materials analysis services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmaceutical, biopharmaceutical, biotechnology and medical device development; Scientific analytical laboratory services; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of pharmaceutical drug, pharmaceutical excipient, and consumer healthcare chemical development; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of pharmaceutical drug, pharmaceutical excipient, and consumer healthcare chemical development; Analytical services, namely, providing Good Laboratory Practices (GLP) testing and quality assurance services to assess clinical performance in the field of therapeutic drug evaluation and development |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, March 6, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Wednesday, May 17, 2023 |
| First Use In Commerce Date | Wednesday, May 17, 2023 |
| Party Name | Alliance Pharma Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Malvern, PA 19355 |
| Party Name | Alliance Pharma Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Malvern, PA 19355 |
| Party Name | Alliance Pharma Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Malvern, PA 19355 |
| Event Date | Event Description |
| Monday, March 6, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, February 18, 2023 | NEW APPLICATION ENTERED |
| Tuesday, November 14, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, November 14, 2023 | NON-FINAL ACTION WRITTEN |
| Tuesday, November 14, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, November 14, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, November 28, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, November 28, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, November 29, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, December 2, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 20, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 9, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 9, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 5, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, April 1, 2024 | USE AMENDMENT FILED |
| Monday, April 1, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Friday, April 19, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, April 19, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| Tuesday, April 30, 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Tuesday, April 30, 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Tuesday, June 4, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, June 4, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |